Tennessee Oncology, New York Cancer & Blood Specialists, and West Cancer Center has joined up to form OneOncology, a technology platform that utilizes Flatiron Health's OncoCloud Suite, which includes OncoEMR, the company's electronic medical records management system.
Through a combination of payment reductions, some provisions of the 2019 Medicare Physician Fee Schedule proposed rule will undermine access to cancer care for Medicare beneficiaries, the American Society of Clinical Oncology wrote in a comment letter to the Centers for Medicare & Medicaid Services.
The discussions that took place in the executive offices of Memorial Sloan Kettering Cancer Center over the past week aren't publicly known. Ditto conversations at top-tier medical journals and professional societies, which are assessing the aftermath of José Baselga's systematic failure to disclose his conflicts of interest.
José Baselga has resigned from his position as physician-in-chief and chief medical officer of Memorial Sloan Kettering Cancer Center less than a week after The New York Times and ProPublica reported that he had failed to disclose his conflicts of interest in scientific and medical journals and at professional meetings.
José Baselga, physician-in-chief and chief medical officer of Memorial Sloan Kettering Cancer Center, has apologized to his executive team for “failing to make appropriate disclosures in scientific and medical journals and at professional meetings.”
Moody Wharam Jr., professor emeritus of radiation oncology and molecular radiation sciences, and former Willard and Lillian Hackerman Professor of Radiation Oncology at the Johns Hopkins Kimmel Cancer Center, died Aug. 10 at age 77.
Vinay Prasad, a cyber-iconoclast for all things cancer, appears to have closed the Twitter account that made him a brand in oncology.
The Janssen Pharmaceutical Companies of Johnson & Johnson announced the FDA approval of Imbruvica (ibrutinib) in combination with rituximab for the treatment of Waldenström's macroglobulinemia.
FDA approved lenvatinib capsules (Lenvima) for first-line treatment of patients with unresectable hepatocellular carcinoma.
Eisai and Merck said the European Commission granted a marketing authorization for the oral receptor tyrosine kinase inhibitor Lenvima (lenvatinib), as a single agent for the first-line treatment of adult patients with advanced or unresectable hepatocellular carcinoma who have received no prior systemic therapy.